{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:19:56Z","timestamp":1781623196019,"version":"3.54.5"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Phosphodiesterase 4 (PDE4) inhibitors hold promise for treating neuroinflammatory and neurodegenerative disorders, but their clinical application in central nervous system (CNS) diseases has been limited by insufficient brain penetration and adverse effects, especially nausea and vomiting. In this study, we characterize compound 11h, a novel, orally available, brain-penetrant PDE4 inhibitor designed to address these limitations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>11h was evaluated using integrated computational, in vitro, and in vivo approaches, including Schr\u00f6dinger-based molecular docking against human PDE4A10, luminescence-based cAMP assays for PDE4 isoform inhibition, and inflammatory assays in murine macrophages, microglia-like cells, and human PBMCs. In vivo efficacy, pharmacokinetics, brain and tissue distribution, tolerability, emesis liability, and behavioral effects were assessed across mouse, rat, and ferret models, alongside comprehensive safety pharmacology encompassing CYP450 inhibition, cardiac ion channel profiling, mutagenicity, and off-target screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      11h demonstrated potent, broad-spectrum inhibition across all four PDE4 isoforms, including key PDE4D splice variants (PDE4D2, PDE4D3), with low nanomolar IC50 values.\n                      <jats:italic>In vitro<\/jats:italic>\n                      , 11h significantly reduced the release of tumor necrosis factor alpha (TNF\u03b1), interleukin 6 (IL-6), and nitrites in lipopolysaccharide (LPS)-stimulated macrophages, microglia-like cells, and human peripheral blood mononuclear cells without affecting cell viability.\n                      <jats:italic>In vivo<\/jats:italic>\n                      , 11h attenuated neuroinflammation in LPS-treated mice by decreasing M1 macrophages and CD4+ T cells, increasing M2 macrophages, and downregulating pro-inflammatory cytokines and MyD88 pathway genes. Pharmacokinetic analysis in rats confirmed strong oral bioavailability, dose-proportional systemic exposure, and sustained brain concentrations exceeding plasma levels for up to 48 h post-dose. Importantly, 11h did not induce vomiting in the ferret emesis model even at doses exceeding 50-fold the efficacious levels in rodent disease models, and was well tolerated in behavioral assays, where it produced anxiolytic-and antidepressant-like effects. Safety profiling revealed no cytotoxicity, genotoxicity, or significant inhibition of cardiac ion channels or cytochrome P450 enzymes. Consistent with this experimental profile, molecular docking suggested that 11h preferentially engages a pocket within the PDE4 catalytic domain, with high predicted binding affinity and ligand efficiency driven by hydrophobic and electrostatic interactions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that 11h provides broad PDE4 inhibition with a favorable tolerability and pharmacokinetic profile relative to approved PDE4 inhibitors, supporting its further development as a therapeutic candidate for CNS disorders characterized by neuroinflammation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1720327","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:35:55Z","timestamp":1767854155000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacological characterization and preclinical evaluation of 11h: a novel, brain-penetrant PDE4 inhibitor for neurological disorders"],"prefix":"10.3389","volume":"16","author":[{"given":"Jacob","family":"Lackovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sougata","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Jane","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel H.","family":"Greig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tweedie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Beiranvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uksha","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dev","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Varadhachary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/s41386-024-01852-z","article-title":"Protective effect of PDE4B subtype-specific inhibition in an App knock-in mouse model for Alzheimer's disease","volume":"49","author":"Armstrong","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"629279","DOI":"10.3389\/fncel.2021.629279","article-title":"Validation of induced microglia-like cells (iMG cells) for future studies of brain diseases","volume":"15","author":"Banerjee","year":"2021","journal-title":"Front. Cell Neurosci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/s0022-3565(25)09664-8","article-title":"Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site","volume":"273","author":"Barnette","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.tips.2019.10.006","article-title":"Phosphodiesterase type 4 inhibition in CNS diseases","volume":"40","author":"Blokland","year":"","journal-title":"Trends Pharmacol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neurobiolaging.2019.01.014","article-title":"Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study","volume":"77","author":"Blokland","year":"","journal-title":"Neurobiol. Aging"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1038\/npp.2014.106","article-title":"Improved long-term memory via enhancing cGMP-PKG signaling requires cAMP-PKA signaling","volume":"39","author":"Bollen","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3390\/biology10121355","article-title":"Assessment of PDE4 inhibitor-induced hypothermia as a correlate of nausea in mice","volume":"10","author":"Boyd","year":"2021","journal-title":"Biology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.pbb.2010.09.013","article-title":"Comparison of the elevated plus and elevated zero mazes in treated and untreated male Sprague-Dawley rats: effects of anxiolytic and anxiogenic agents","volume":"97","author":"Braun","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B9","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/sj.bjp.0702387","article-title":"The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay","volume":"126","author":"Brideau","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nbt.1598","article-title":"Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety","volume":"28","author":"Burgin","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1021\/acschemneuro.0c00170","article-title":"KVA-D-88, a novel preferable phosphodiesterase 4B inhibitor, decreases cocaine-mediated reward properties in vivo","volume":"11","author":"Burkovetskaya","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"B12","first-page":"148","article-title":"Molecular mechanisms of psychostimulant addiction","volume":"32","author":"Chen","year":"2009","journal-title":"Chang. Gung Med. J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"382","DOI":"10.2174\/0118715273337232241121113048","article-title":"Anti-neuroinflammatory and neuroprotective effects of T-006 on Alzheimer's Disease models by modulating TLR4-Mediated MyD88\/NF-\u03baB signaling","volume":"24","author":"Chen","year":"2025","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12974-025-03428-0","article-title":"Microglia efferocytosis: an emerging mechanism for the resolution of neuroinflammation in Alzheimer's disease","volume":"22","author":"Chen","year":"2025","journal-title":"J. Neuroinflammation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/ijnp\/pyad042","article-title":"Rolipram ameliorates memory deficits and depression-like behavior in APP\/PS1\/tau triple transgenic mice: involvement of neuroinflammation and apoptosis via cAMP signaling","volume":"26","author":"Cong","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1074\/jbc.R200029200","article-title":"Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling","volume":"278","author":"Conti","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1006\/abio.1997.2145","article-title":"Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450","volume":"248","author":"Crespi","year":"1997","journal-title":"Anal. Biochem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"117009","DOI":"10.1016\/j.biopha.2024.117009","article-title":"Beyond PDE4 inhibition: a comprehensive review on downstream cAMP signaling in the central nervous system","volume":"177","author":"Donders","year":"2024","journal-title":"Biomed. & Pharmacother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1021\/jm9505066","article-title":"Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret","volume":"39","author":"Duplantier","year":"1996","journal-title":"J. Med. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3451461","DOI":"10.1155\/2019\/3451461","article-title":"The cAMP pathway amplifies early MyD88-Dependent and type I interferon-independent LPS-induced Interleukin-10 expression in mouse macrophages","volume":"2019","author":"Ernst","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"B21","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1056\/NEJMoa1803583","article-title":"Phase 2 trial of ibudilast in progressive multiple sclerosis","volume":"379","author":"Fox","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1111\/j.1476-5381.1995.tb15118.x","article-title":"The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040","volume":"116","author":"Gardner","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00213-018-5134-y","article-title":"An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients","volume":"238","author":"Gilleen","year":"2021","journal-title":"Psychopharmacol. Berl."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1172\/JCI22831","article-title":"Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment","volume":"114","author":"Gong","year":"2004","journal-title":"J. Clin. Invest."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1111\/j.1476-5381.1991.tb12362.x","article-title":"Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits","volume":"103","author":"Holbrook","year":"1991","journal-title":"Br. J. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0014-2999(96)00969-7","article-title":"Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents","volume":"321","author":"Imanishi","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/s0026-895x(25)09391-5","article-title":"Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding","volume":"50","author":"Jacobitz","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00213-009-1594-4","article-title":"The involvement of type IV phosphodiesterases in cocaine-induced sensitization and subsequent pERK expression in the mouse nucleus accumbens","volume":"206","author":"Janes","year":"2009","journal-title":"Psychopharmacol. Berl."},{"key":"B29","doi-asserted-by":"publisher","first-page":"7628","DOI":"10.1073\/pnas.122041599","article-title":"Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses","volume":"99","author":"Jin","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.4049\/jimmunol.175.3.1523","article-title":"Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse Macrophages1","volume":"175","author":"Jin","year":"2005","journal-title":"J. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"11518","DOI":"10.3390\/ijms241411518","article-title":"PDE4 inhibitors: profiling hits through the multitude of structural classes","volume":"24","author":"Jin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1756-6606-5-14","article-title":"The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and CPEB","volume":"5","author":"Kandel","year":"2012","journal-title":"Mol. Brain"},{"key":"B33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12868-023-00810-7","article-title":"Differential effects of two phosphodiesterase 4 inhibitors against lipopolysaccharide-induced neuroinflammation in mice","volume":"24","author":"Kang","year":"2023","journal-title":"BMC Neurosci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3109\/00498258809041693","article-title":"Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences","volume":"18","author":"Krause","year":"1988","journal-title":"Xenobiotica"},{"key":"B35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"Lakics","year":"2010","journal-title":"Neuropharmacology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/npp.2009.66","article-title":"Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus","volume":"34","author":"Li","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1038\/npp.2017.96","article-title":"PDE4 inhibition restores the balance between excitation and inhibition in VTA dopamine neurons disrupted by repeated in vivo cocaine exposure","volume":"42","author":"Liu","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0165-1161(83)90010-9","article-title":"Revised methods for the Salmonella mutagenicity test","volume":"113","author":"Maron","year":"1983","journal-title":"Mutat. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"12533","DOI":"10.1096\/fj.202001016RR","article-title":"PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice","volume":"34","author":"McDonough","year":"2020","journal-title":"Faseb J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/syn.10100","article-title":"Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization","volume":"45","author":"Mir\u00f3","year":"2002","journal-title":"Synapse"},{"key":"B42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1590\/s1516-44462009000200012","article-title":"The psychiatric side-effects of rimonabant","volume":"31","author":"Moreira","year":"2009","journal-title":"Braz J. Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jchemneu.2010.03.004","article-title":"The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D","volume":"40","author":"Mori","year":"2010","journal-title":"J. Chem. Neuroanat."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1016\/j.bmcl.2009.04.121","article-title":"Discovery of selective PDE4B inhibitors","volume":"19","author":"Naganuma","year":"2009","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B45","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00018-023-04804-w","article-title":"Ablation of specific long PDE4D isoforms increases neurite elongation and conveys protection against amyloid-\u03b2 pathology","volume":"80","author":"Paes","year":"2023","journal-title":"Cell Mol. Life Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/glia.22986","article-title":"PDE4B as a microglia target to reduce neuroinflammation","volume":"64","author":"Pearse","year":"2016","journal-title":"Glia"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/s0891-0618(00)00097-1","article-title":"Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain","volume":"20","author":"P\u00e9rez-Torres","year":"2000","journal-title":"J. Chem. Neuroanat."},{"key":"B49","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2165\/00003088-200241100-00005","article-title":"Enterohepatic circulation: physiological, pharmacokinetic and clinical implications","volume":"41","author":"Roberts","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/s0028-3908(98)00190-7","article-title":"Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret","volume":"38","author":"Robichaud","year":"1999","journal-title":"Neuropharmacology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"14250","DOI":"10.1021\/bi971112e","article-title":"Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities","volume":"36","author":"Rocque","year":"1997","journal-title":"Biochemistry"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.7150\/thno.50701","article-title":"PDE inhibition in distinct cell types to reclaim the balance of synaptic plasticity","volume":"11","author":"Rombaut","year":"2021","journal-title":"Theranostics"},{"key":"B53","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.3390\/ijms25126424","article-title":"Mechanisms underlying the effects of chloroquine on red blood cells metabolism","volume":"25","author":"Russo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3109\/00498250903254340","article-title":"Cross-species comparisons of the pharmacokinetics of ibudilast","volume":"39","author":"Sanftner","year":"2009","journal-title":"Xenobiotica"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2022.12.020","article-title":"Selective PDE4 subtype inhibition provides new opportunities to intervene in neuroinflammatory versus myelin damaging hallmarks of multiple sclerosis","volume":"109","author":"Schepers","year":"2023","journal-title":"Brain, Behav. Immun."},{"key":"B56","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12974-022-02565-0","article-title":"Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer's disease","volume":"19","author":"Singh","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/nprot.2012.044","article-title":"Using the rat forced swim test to assess antidepressant-like activity in rodents","volume":"7","author":"Slattery","year":"2012","journal-title":"Nat. Protoc."},{"key":"B58","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fnagi.2017.00139","article-title":"Pharmacological modulation of functional phenotypes of microglia in neurodegenerative diseases","volume":"9","author":"Song","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/s0898-6568(96)00173-8","article-title":"Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases","volume":"9","author":"Souness","year":"1997","journal-title":"Cell Signal"},{"key":"B60","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12974-016-0693-5","article-title":"A murine model of inflammation-induced cerebral microbleeds","volume":"13","author":"Sumbria","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00210-017-1406-z","article-title":"PK\/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response","volume":"390","author":"\u015awierczek","year":"2017","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e0198943","DOI":"10.1371\/journal.pone.0198943","article-title":"Evaluation of phenotypic and functional stability of RAW 264.7 cell line through serial passages","volume":"13","author":"Taciak","year":"2018","journal-title":"PLoS One"},{"key":"B63","doi-asserted-by":"publisher","first-page":"7095","DOI":"10.1523\/JNEUROSCI.3212-15.2016","article-title":"Chronic cognitive dysfunction after traumatic brain injury is improved with a phosphodiesterase 4B inhibitor","volume":"36","author":"Titus","year":"2016","journal-title":"J. Neurosci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1021\/acsmedchemlett.9b00369","article-title":"Synthesis and SAR studies of 1H-Pyrrolo[2,3-b]pyridine-2-carboxamides as phosphodiesterase 4B (PDE4B) inhibitors","volume":"11","author":"Vadukoot","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1111\/acer.14669","article-title":"Increased toll-like Receptor-MyD88-NF\u03baB-Proinflammatory neuroimmune signaling in the orbitofrontal cortex of humans with alcohol use disorder","volume":"45","author":"Vetreno","year":"2021","journal-title":"Alcohol Clin. Exp. Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/0028-3908(86)90159-0","article-title":"Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors","volume":"25","author":"Wachtel","year":"1986","journal-title":"Neuropharmacology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/nprot.2007.44","article-title":"The use of the elevated plus maze as an assay of anxiety-related behavior in rodents","volume":"2","author":"Walf","year":"2007","journal-title":"Nat. Protoc."},{"key":"B68","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jad.2023.12.074","article-title":"Roflumilast: modulating neuroinflammation and improving motor function and depressive symptoms in multiple sclerosis","volume":"350","author":"Wang","year":"2024","journal-title":"J. Affect Disord."},{"key":"B69","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1159\/000288734","article-title":"Pharmacokinetic-pharmacodynamic modeling of methylxanthine derivatives in mice challenged with high-dose lipopolysaccharide","volume":"85","author":"Wyska","year":"2010","journal-title":"Pharmacology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1055\/s-2007-1017435","article-title":"Results of a phase II study of the antidepressant effect of rolipram","volume":"17","author":"Zeller","year":"1984","journal-title":"Pharmacopsychiatry"},{"key":"B71","doi-asserted-by":"publisher","first-page":"40115","DOI":"10.1038\/srep40115","article-title":"Comparison of the pharmacological profiles of selective PDE4B and PDE4D inhibitors in the central nervous system","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"B72","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/cns.13807","article-title":"Inhibition of phosphodiesterase-4 in the spinal dorsal horn ameliorates neuropathic pain via cAMP-cytokine-Cx43 signaling in mice","volume":"28","author":"Zhang","year":"2022","journal-title":"CNS Neurosci. Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fnmol.2019.00314","article-title":"Inflammatory role of TLR-MyD88 signaling in multiple sclerosis","volume":"12","author":"Zheng","year":"2019","journal-title":"Front. Mol. Neurosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1720327\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:35:56Z","timestamp":1767854156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1720327\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":73,"alternative-id":["10.3389\/fphar.2025.1720327"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1720327","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"article-number":"1720327"}}